Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, review timing and choice of first-line antiretroviral therapy in this unique program with a didactic video module and several case-based vignettes in which you are invited to help manage the patient.
Upon completion of this activity, participants should be able to:
TURQUOISE-I: High SVR12 Rates With ABT-450/Ritonavir/Ombitasvir + Dasabuvir + RBV in HIV/Genotype 1 HCV–Coinfected Patients on Stable Atazanavir- or Raltegravir-Based ART
Evolving Switch Strategies for Virologically Suppressed HIV-Infected Patients
PHOTON-2: Sofosbuvir + Ribavirin Yields High SVR12 Rates in Patients Coinfected With HIV and Genotypes 1-4 HCV
Using Boosted Protease Inhibitors in the Aftermath of ACTG 5257
What 5257 Tells Us About the Selection of Integrase Inhibitor Regimens For HIV Therapy
Clinical Care Options, LLC. All Rights Reserved.